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Functional single-nucleotide polymorphisms (SNPs) of inﬂammatory cytokines have been previously related to the occurrence
of an ischemic stroke (IS). We investigated whether ﬁve functional SNPs (i.e., TNF-α -308G>A, IL6-174G>C, IL12B 1188A>C,
IL4-589C>T, and IL10-1082G>A) might be associated with the age of onset and 6-month outcome of an acute IS. A probe-free
real-time PCR methodology was used to genotype 145 consecutively admitted cases with a ﬁrst-ever IS. SimpleKaplan-Mayer and
adjusted Cox regression analyses showed no association between inﬂammatory genotypes and the age of IS onset. IL6-174G>C,
IL12B 1188A>C, IL4-589C>T, and IL10-1082G>A were not found to signiﬁcantly contribute to the long-term outcome of the
disease.However,carriage ofthe TNF-α -308 GG genotype was signiﬁcantlyassociatedwith reduced odds foran adverse outcome.
Larger studies are needed to conﬁrm our results.
1.Introduction
In the last decade, inﬂammatory mechanisms have been
implicated both in the manifestation and evolution of brain
ischemia [1]. Immune inﬂammatory processes may in time
predispose to ischemic stroke (IS) through precipitation of
atherosclerotic disease [2] and sustainment of atrial ﬁbrilla-
tion [3]. Moreover, salvation of the ischemic penumbra and
ﬁnal size ofthebraininfarct, bothofwhich strongly correlate
toclinicaloutcomeafteranIS,seemtobemassivelyregulated
by networks of poststroke inﬂammatory responses [4, 5].
Thus,proinﬂammatory andanti-inﬂammatory cytokinesare
important mediators of the pathophysiological events which
precede an acute IS [6] and have been further related to the
clinical outcome of the disease (reviewed in [7]).
Among the various proinﬂammatory cytokines, tumor
necrosis factor-alpha (TNF-α) and interleukin (IL) 6 seem to
actively participate in the immune-mediated inﬂammation
of stroke [5, 8]. IL12 is an important regulatory cytokine
with proinﬂammatory inclination [9], which is also found
upregulated during stroke [10]. IL4 and IL10 are cytokines
of the anti-inﬂammatory arm which counteract the actions
of proinﬂammatory molecules, and have been found sup-
pressed prior to, as well as after a cerebral ischemic event
[11–13].
On grounds of genetic regulation, the production of
these inﬂammatory cytokines seems to be signiﬁcantly
inﬂuenced by the presence of point mutations located
within regulatory gene regions, known as functional single-
nucleotide polymorphisms (SNPs) [14]. SNP-association
studies of inﬂammatory cytokines have been previously
conducted in cases of IS, under the hypothesis that a genetic
predisposition to enhanced (or suppressed) production of
T-helper 1 (Th1) or Th2 cytokines could possibly modify
the risk of the disease (reviewed in [15]). However, so far,
none of these studies has addressed the question of whether
such functional genetic variances could predispose to the
prematureonsetofcerebrovascular diseaseoralteritsclinical
outcome.
In the present study, we investigated the possible impact
of ﬁve common SNPs into the age of onset and long-term2 Stroke Research and Treatment
Table 1: Allele-speciﬁc primers and real-time PCR conditions.
Allele-speciﬁc primers Real-time PCR conditions
IL4-589C>T
Segment 1-Ampliﬁcation (40 cycles)
(i) Denaturation at 95◦Cf o r3 0
  
(ii) Annealing at 56◦Cf o r3 0
  
(iii) Extension at 72◦Cf o r2 0
  
Segment 2-Qualitative data collection (115
cycles):
70–95◦Cf o r1 8
  
(Speciﬁcally for TNF-α-308G>A:
annealing at 61◦Cf o r2 5
  )
FRW C primer
FRW T primer
5 -GCGGCGCGGCCCACTAAACTTGGGAGAACATTGAC-3 
5 -AGTAAACTTGGGAGAACATTGTT-3 
REV primer 5 -GGCAGAATAACAGGCAGAC-3 
IL10-1082G>A
FRW G primer
FRW A primer
5 -GCGGCGCGGCGG-TTAGTAAGGCTTCTTTGGGTG -3 
5 -TACTACTAAGGCTTCTTTGGGAA -3 
REV primer 5 -CTGGATAGGAGGTCCCTTAC-3 
TNF-α-308G>A
FRW G primer∗ 5 -GCGGCGCGGCGG-CTGGCTGAACCCCGTCTC-3 
FRW A primer∗ 5 -AGGCTGAACCCCGTGCT-3 
REV primer∗ 5 -AAGGAAACAGACCACAGACCTG-3 
IL6-174G>C
FRW G primer∗ 5 -ATTGTGACGTCCTTTAGCATC-3 
FRW C primer∗ 5 -GCGGGCGGGCCG-ATTGTGACGTCCTTTAGGTTG-3 
REV primer∗ 5 -ATGACGACCTAAGCTGCAC-3 
IL12B 1188A>C
FRW A primer∗ 5 -TTTCAATGAGCATTTAGCAACT-3 
FRW C primer∗ 5 -GCGGCGCGGCGG-TACAATGAGCATTTAGCATGG-3 
REV primer∗ 5 -TAGGATCACAATGATATCTTTGC-3 
∗Primer designed on the complementarysequence. FRW: forward, REV: reverse.
Underlined are sites of introduced mismatches.Bold are the polymorphic alleles. Italic is the intoduced GC-tail.
functional outcome of an acute IS. The studied mutations
included three SNPs of proinﬂammatory cytokines (i.e.,
TNF-α-308G>A, IL6-174G>C, and IL12B 1188A>C), and
two more SNPs concerning the major anti-inﬂammatory
cytokines (i.e., IL4-589C>T, and IL10-1082G>A). These
SNPs have been previously studied in various inﬂammatory
diseases (e.g., rheumatic diseases, asthma, and inﬂammatory
bowel disease) producing positive correlations [16–20]. Each
of the above polymorphisms has been reported to exert
functionalpropertiesininvitro and exvivostudies,following
mitogenic stimulation [16, 21–24]. A more robust evidence
for their functionality has been given for TNF-α-308G>A
which has been found to aﬀect a transcription-binding
s i t ea n dr e s u l ti nt h ef o r m a t i o no fa na l t e r e dt r a n s c r i p t i o n
element [25] and also for IL10-1082G>A which contains
a putative ETS-like transcription factor binding site [26].
2.Methods
2.1. Study Population. We recruited 145 acute IS patients
who presented consecutively at the Emergency Department
of the University Hospital of Patras, Patras, Greece, with
signs and symptoms of a ﬁrst-ever cerebrovascular event,
and were admitted in the Neurology and General Medicine
wardsbetweenSeptember2006andDecember2007.Patients
with intracerebral or subarachnoid haemorrhage, transient
ischemic attacks (TIAs), chronic inﬂammatory/rheumatic
diseases,comorbidmalignancy,andstrokessecondarytorare
conditions (i.e., traumatic carotid dissection, endocarditis)
were excluded from the study. Blood samples and base-
line clinical data were collected upon admittance to the
Emergency Department. Stroke severity on admission was
assessed using the Scandinavian stroke scale. All patients had
a brain computerized tomography (CT) on admission, and a
second brain imaging (CT or magnetic resonance imaging)
during hospitalization. Investig a t i o n ss u c ha sc a r o t i du l t r a -
sonography, carotid CT angiography, transesophageal heart
ultrasonography, serology and coagulation studies, were per-
formed according to patient-speciﬁc clinical criteria. Stroke
subtype classiﬁcation was based on TOAST deﬁnitions [27].
As conﬁrmed at the baseline interview, participants were
Caucasian in origin, and provided their informed consent at
inclusion. The study protocol was approved by the Ethical
Committee of the University Hospital of Patras.
2.2. Data and Clinical Assessments. Demographics, past
medical history, and conventional stroke risk factors were
collected at inclusion. Arterial hypertension was considered
present if it was clearly documented (>140/90mmHg) or
when treated. Diabetes mellitus was deﬁned as fasting
glucose >126mg/dL or current use of antidiabetic medica-
tion. Hypercholesterolemia was noted if fasting cholesterol
levels were >220mg/dL or when treated. History of angina,
myocardial infarction and heart failure were assembled in
“ischemic heart disease”. Smoking, either active or ceased
within the last 6 months, was recorded as current. By
vascular death, we considered death in relation to vascu-
lar complications (i.e., stroke, myocardial infarction, pul-
monary embolism, and deep vein thrombosis). Patients wereStroke Research and Treatment 3
Table 2: Baseline characteristics and genotype frequencies of IS
patients.
Characteristic IS patients
(n = 145)
Age, median (IQR) 68 (58–76)
Sex, females (%) 50 (34.5)
Arterial hypertension (%) 104 (72)
Diabetes mellitus (%) 40 (28)
Hypercholesterolemia (%) 102 (70)
Atrial ﬁbrillation (%) 31 (21)
Ischemic heart disease (%) 37 (26)
Current smoking(%) 52 (36)
Stroke severity on admission(%)
Mild (SSS = 45–58) 69 (48)
Moderate (SSS = 19–44) 44 (30)
Severe (SSS = 0–18) 32 (22)
TNF-α-308G>A
GG (%) 115 (79)
GA (%) 30 (21)
IL6-174G>C
GG (%) 85 (59)
GC (%) 50 (34)
CC (%) 10 (7)
IL12B 1188A>C
AA (%) 77 (53)
AC (%) 57 (39)
CC (%) 11 (8)
IL4-589C>T
CC (%) 123 (84.8)
CT (%) 22 (15.2)
IL10-1082G>A
AA (%) 47 (32.4)
GA (%) 71 (49)
GG (%) 27 (18.6)
IQR: interquartile range, IS: ischemicstroke,
SSS: scandinavian stroke scale.
followed-up for 6 months registering medications, disease
relapses, deaths, and functional outcome measured by the
Barthel Index (BI), which is a reliable and widely used
disability scale [28].
2.3. DNA Extraction and Genotyping Assays. DNA was
extracted from whole blood in EDTA, according to standard
puriﬁcation protocols by Qiagen, QIAamp DNA blood Mini
Kit, and stored at −80◦C until use. For the genotyping,
we applied a real-time polymerase chain reaction (RT-
PCR) technique, which discriminates alleles by detecting
diﬀerences in the melting temperatures of the products
(Tm). Diﬀerences in Tm are produced by the introduction
of a GC-tail at the end of one of the two allele-speciﬁc
primers [29], and measured by SYBR Green ﬂuorescence.
For the studied SNPs, the method was used for the
ﬁrst time. Prototypically designed primers and conditions
Table 3: Statistics of the disease-free survival analysis.
Disease-free survival analysis
Median (SE) KM log rank Cox regression∗
P Odds ratio (95% CI)
TNF-α-308G>A
GA 65 (4.93) .70 Referent
GG 68 (1.97) 0.74 (0.49–1.12)
IL6-174G>C
GG 65 (2.01) .86 Referent
GC/CC 69 (1.66) 0.70 (0.51–1.22)
IL12B 1188A>C
AA 67 (2.00) .62 Referent
AC/CC 70 (2.58) 1.02 (0.72–1.44)
IL4-589C>T
CC 67 (2.08) .91 Referent
CT 68 (4.10) 1.07 (068–1.70)
IL10-1082G>A
GA/AA 68 (2.09) .55 Referent
GG 65 (6.06) 1.43 (0.92–2.22)
SE: standard error, KM: Kaplan-Mayer, CI: conﬁdence intervals.
∗Adjustedfor sex,hypertension, diabetes,hyperlipidemia,atrialﬁbrillation,
ischemicheart disease, and smoking.
can be seen in Table 1. Primers were designed using the
DNAman version 4.02 software, tested for speciﬁcity with
BLAST (http://blast.ncbi.nlm.nih.gov/), and synthesized by
Metabion International AG, Germany. All samples were pro-
cessedinduplicates,andgenotypingof10%randomsamples
f orea c hSNPw a sc on ﬁ rm edb ys equen ci n g(V BC- BIO T ECH
Service GmbH, Sequencing Unit, Vienna, Austria). Analyses
were employed in the Stratagene Mx3000P qPCR machine,
using the Brilliant QPCR MasterMix by Stratagene, La Jolla,
USA.
2.4. Statistical Analysis. AK a p l a n - M a y e rd i s e a s e - f r e es u r -
vival analysis was used to test for possible diﬀerences
in the age of IS onset, depending on the carriage of
speciﬁc inﬂammatory genotype. Statistical signiﬁcance was
expressed with P log ranks. Cox regression analyses were
further conducted for each SNP to include possible known
confounders (i.e., sex, hypertension, diabetes, atrial ﬁbrilla-
tion, hyperlipidemia, smoking) in the overall eﬀect.To assess
thepotentialgeneticcontributionintheoddsofhavingabad
functional outcome, a binary logistic regression analysis was
applied after adjustments for age, sex, vascular risk factors,
stroke severity on admission and TOAST categories. Data
of the regressions are given as Odds Ratios (OR) with 95%
conﬁdence intervals (95% CI).
3.Results
Baseline characteristics and genotypes of the studied poly-
morphisms inourIScohortare seenonTable 2.Allgenotype
frequencieswerefoundinaccordancetotheHardy-Weinberg4 Stroke Research and Treatment
Table 4: Associationof inﬂammatory genotypes with long-term functional outcome of an IS.
Genotypes Logistic regression
TNF-α-308G>AP r e s e n c e o f G G
6-month outcome AG GG OR∗ 95% CI P
(BI: 16–20) good (%)
(BI: <16, or death) bad (%)
15 (17)
13 (25.5)
73 (83)
38 (74.5)
Referent
0.19 0.04–0.86 .03
IL6-174G>C Presence of GC/CC
GG GC/CC OR∗ 95% CI P
(BI: 16–20) good (%)
(BI: <16, or death) bad (%)
54 (64.3)
34 (62.8)
30 (35.7)
21 (38.2)
Referent
1.14 0.37–3.54 .82
IL12B 1188A>CP r e s e n c e o f A C
AA/CC AC OR∗ 95% CI P
(BI: 16–20) good (%)
(BI: <16, or death) bad (%)
48 (54.5)
37 (72.5)
40 (45.5)
14 (27.5)
Referent
0.69 0.23–2.09 .52
IL4-589C>TP r e s e n c e o f C T
CC CT OR∗ 95% CI P
(BI: 16–20) good (%)
(BI: <16, or death) bad (%)
71 (84.1)
43 (84.3)
14 (15.9)
8 (15.7)
Referent
0.67 0.17–2.59 .56
IL10-1082G>AP r e s e n c e o f G G
GG AG/AA OR∗ 95% CI P
(BI: 16–20) good (%)
(BI: <16, or death) bad (%)
14 (15.9)
12 (23.5)
74 (84.1)
39 (76.5)
Referent
2.65 0.57–12.40 .22
BI: barthel index, OR: odds ratio, CI: conﬁdence intervals.
∗ORs adjusted for age, sex, hypertension, diabetes, hyperlipidemia, ischemicheart disease, smoking, stroke severity on admission and TOAST categories.
equilibrium, that is, for TNF-α-308G>A P = .17, for IL6-
174G>C P = .48, for IL12B 1188A>C P = .92, for IL4-
589C>T P = .32, and for IL10-1082G>A P = .98.
Figure 1 shows the Kaplan-Mayer curves for the disease-
freesurvivalanalysisdependingongenotypesofeachstudied
inﬂammatory SNP. As seen on the curves, carriers of
the ancestral alleles did not signiﬁcantly diﬀer in the age
of stroke onset compared to their homo- and heterozy-
gous mutant counterparts. Estimates of median (standard
error) age of IS onset for each inﬂammatory genotype,
as well as the Kaplan-Mayer P log ranks can be seen on
Table 3. A Cox regression analysis was further applied to
correct the impact of studied genotypes on the age of
disease onset, for other important confounders (i.e., sex,
hypertension, diabetes, hyperlipidemia, atrial ﬁbrillation,
ischemic heart disease, and smoking). ORs with 95%
CI of the adjusted genotype eﬀects conﬁrmed a lack of
association between inﬂammatory SNPs and disease-free
survival (Table 3). Interestingly, in all regressions, the most
powerful predictors of the premature age of IS onset were
smoking and hyperlipidemia (both P<. 001, data not
shown).
Because Kaplan-Mayer curves (Figure 1)i n v o l v i n gT N F -
α-308G>A, IL4-589C>T and IL10-1082G>Ap r e s e n t e dd i f -
ferentiating slopes approximately before the age of 65, we
reapplied the above analysis separately for this younger
age-group (n = 76). However, neither this subanalysis
could point to signiﬁcant diﬀerences in the age of IS
onset between the diﬀerent inﬂammatory genotypes. The
subsequent Cox regression (OR (95% CI)) also showed no
signiﬁcant contribution of TNF-α-308GG (0.70 (0.37–1.35),
IL4-589CT(0.53(0.26–1.07)),orIL10-1082GG (1.83(0.97–
3.47)) genotypes, after standard adjustments for sex and
vascular risk factors.
Table 4 contains the genotypic distributions across cat-
egories of good and bad functional outcome, at 6 months
after IS. Bad functional outcome included cases with BI<16,
or death. Combinations of genotypes have been made
so as to unite groups of “high” versus “low” cytokine
producers. The binary logistic regression showed a statistical
signiﬁcant contribution of the TNF-α-308 GG ancestral
genotype in the reduction of the odds for an adverse 6-
month outcome (OR (95% CI) = 0.19 (0.04–0.86)), even
after important corrections for age, sex, vascular risk factors,
stroke severity on admission and TOAST categories. For the
rest of the inﬂammatory SNPs, no similar association could
be conﬁrmed. As expected, stroke severity on admission was
the most powerful predictor in the models (P<. 001, data
not shown).
4.Discussion
Inthelastdecade,experimentalaswellasclinicalstudieshave
recognized both pro and anti-inﬂammatory cytokines as
key mediators of the low-grade aseptic inﬂammation, which
precedes an ischemic cerebrovascular event and follows its
pathophysiologicalcourse[1].SNPsthataltertheproduction
rate of inﬂammatory cytokines secondary to a given trigger,
have been previously related to incident IS [15]. The presentStroke Research and Treatment 5
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Figure 1: Kaplan-Mayer curves for the disease-free survival analysis,according to the studied inﬂammatory genotypes.
study investigated the possible genetic contribution of
functionalpolymorphismsofmajorinﬂammatory molecules
(i.e., TNF-α-308G>A, IL6-174G>C, IL12B 1188A>C, IL4-
589C>T and IL10-1082G>A) in the age of onset and 6-
month outcome of an acute IS. Genotyping was based on a
PCR-allele discrimantion technique without oligonucleotide
probes [29], which yielded comparable allele frequencies to
those previously reported using diﬀerent methods [30–34].
Despite previous promising data suggesting a signiﬁcant
association of the age of onset of Alzheimer’s disease with
genotypes of TNF-α-308G>A SNP [35], our results showed
that the age of onset of ischemic cerebrovascular disease may
notbepredictedbyinﬂammatory genotypes.SimpleKaplan-
Mayer disease-free survival curves, as well as Cox regressions
adjusted for sex and vascular risk factors, conﬁrmed that
IS is a complex, multifactorial clinical phenotype, which6 Stroke Research and Treatment
can manifest prematurely or delayed, irrespectively of the
genetic inﬂammatory burden. Furthermore, it is possible
that the gross eﬀect of conventional vascular risk factors in
the incidence of IS may not be easily overwhelmed. Under
this rationale, it would be interesting to know whether the
reported genotype frequencies diﬀer from those of a healthy
population. This investigation could be the aim of a future
case-control association study.
Although genome-wide association studies are reason-
ably more relevant to detect combinations ofgenetic traits in
relation to a speciﬁc clinical phenotype over a large number
of patients, they tend to miss important clinical aspects
of the disease. This is why, smaller-scale SNP association
studies of molecules which have some a priori evidence for a
pathogenicroleinthediseaseofinterest,maystillbeusefulin
implying possible relations with meaningful clinical impact.
Under this scope, we set to investigate whether our selected
inﬂammatory functional SNPs could predict the long-term
outcomeof an IS. After applying adjusted analyses, we found
a lack of association between IL6-174G>C, IL12B 1188A>C,
IL4-589C>TandIL10-1082G>Aand6-monthoutcomeafter
stroke. The relatively limited number of IS cases included,
maypartiallyexplaintheabovelackofassociations. However,
we were able to identify a signiﬁcant contribution of the
ancestral TNF-α-308 GG genotype in about 80% reduced
odds for having an adverse outcome (OR (95% CI) = 0.19
(0.04–0.86)). This long-term association of TNF-α-308 G-
allele double carriage is in line with its described low TNF-
secreting properties [36]. High TNF-α levels at 3 months
after an IS, have been previously found to relate with
undesired functional dependency [37].
To conclude, our results show that functional genotypes
of important inﬂammatory cytokines cannot either delay or
precipitate the age of IS onset, despite the widely accepted
role of such molecules in the pathophysiology of the disease.
We provide implications for a possible predictive eﬀect
of TNF-α-308 GG ancestral genotype into better clinical
outcome 6 months after stroke. It is possible that the small
size of our study may have not allowed for identiﬁcation of
other statistical signiﬁcant associations. Therefore, further
studies in larger IS cohorts, are needed to conﬁrm our
results.
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